medigraphic.com

2007, Número S4

<< Anterior Siguiente >>

Arch Cardiol Mex 2007; 77 (S4)


Revascularización miocárdica en el 2006

Palazuelos J, Macaya C

Idioma: Español
Referencias bibliográficas: 28
Paginas: 133-138
Archivo PDF: 116.82 Kb.


FRAGMENTO

Las enfermedades cardiovasculares son la principal causa de mortalidad en el mundo, siendo la cardiopatía isquémica una de sus manifestaciones más relevantes. Desde hace tiempo, uno de los aspectos más debatidos es el manejo de los síndromes coronarios agudos (SCA). Desde el punto de vista del manejo de los pacientes se hace necesario distinguir entre aquellos pacientes que debutan con un SCA sin elevación del segmento ST (SCASEST) y aquellos que lo hacen con elevación del segmento ST (SCACEST).


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Boersma E, Maas AC, Deckers JW, Simoons ML: Early thrombolytic treatment in acute myocardial infarction: reappraisal of the golden hour. Lancet 1996; 348 (9030): 771-5.

  2. Stone GW, Cox D, Garcia E, Brodie BR, Morice MC, Griffin J, Mattos L, Lansky AJ, O’Neill: Normal flow (TIMI-3) before mechanical reperfusion therapy is an independent determinant of survival in acute myocardial infarction: analysis from the primary angioplasty in myocardial infarction trials. Circulation 2001; 104(6): 636-41.

  3. Keeley EC, Boura JA, Grines CL: Comparison of primary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomized trials. Lancet 2003; 361: 13-20.

  4. Schömig A, Ndrepepa G, Mehilli J, Schwaiger M, Schühlen H, Nekolla S, et al: Therapy-Dependent Influence of Time-to-Treatment Interval on Myocardial Salvage in Patients With Acute Myocardial Infarction Treated With Coronary Artery Stenting or Thrombolysis. Circulation 2003; 108: 1084-8.

  5. Zijlstra F, Patel A, Jones M, Grines CL, Ellis S, Garcia E, et al: Clinical characteristics and outcome of patients with early (<2 h), intermediate (2-4 h) and late (> 4 h) presentation treated by primary coronary angioplasty or thrombolytic therapy for acute myocardial infarction. Eur Heart J. 2002; 23(7): 550-7.

  6. Danchin N, Blanchard D, Steg PG, Sauval P, Hanania G, Goldstein P, Cambou JP, Gueret P, Vaur L, Boutalbi Y, Genes N, Lablanche JM; USIC 2000 Investigators. Impact of prehospital thrombolysis for acute myocardial infarction on 1-year outcome: results from the French Nationwide USIC 2000 Registry. Circulation 2004; 110(14): 1909-15.

  7. Vermeer F, Oude Ophuis AJ, vd Berg EJ, Brunninkhuis LG, Werter CJ, Boehmer AG, Lousberg AH, Dassen WR, Bar FW: Prospective randomized comparison between thrombolysis, rescue PTCA, and primary PTCA in patients with extensive myocardial infarction admitted to a hospital without PTCA facilities: a safety and feasibility study. Heart 1999; 82(4): 426-31.

  8. Madsen JK, Grande P, Saunamaki K, Thayssen P, Kassis E, Eriksen U, Rasmussen K, Haunso S, Nielsen TT, Haghfelt T, Fritz-Hansen P, Hjelms E, Paulsen PK, Alstrup P, Arendrup H, Niebuhr-Jorgensen U, Andersen LI: Danish multicenter randomized study of invasive versus conservative treatment in patients with inducible ischemia after thrombolysis in acute myocardial infarction (DANAMI). DANish trial in Acute Myocardial Infarction. Circulation 1997; 96(3): 748-55.

  9. Andersen HR, Nielsen TT, Rasmussen K, Thuesen L, Kelbaek H, Thayssen P, Abildgaard U, Pedersen F, Madsen JK, Grande P, Villadsen AB, Krusell LR, Haghfelt T, Lomholt P, Husted SE, Vigholt E, Kjaergard HK, Mortensen LS; DANAMI-2 Investigators. A comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial infarction. N Engl J Med 2003; 349(8): 733-42.

  10. Grines CL, Westerhausen DR Jr, Grines LL, Hanlon JT, Logemann TL, Niemela M, Weaver WD, Graham M, Boura J, O’Neill WW, Balestrini C; Air PAMI Study Group. A randomized trial of transfer for primary angioplasty versus on-site thrombolysis in patients with high-risk myocardial infarction: the Air Primary Angioplasty in Myocardial Infarction study. J Am Coll Cardiol 2002; 39(11): 1713-9. (Air-PAMI).

  11. Betriu A, Masotti M: Comparison of mortality rates in acute myocardial infarction treated by percutaneous coronary intervention versus fibrinolysis. Am J Cardiol 2005; 95(1): 100-1.

  12. Widimsky P, Groch L, Zelizko M, Aschermann M, Bednar F, Suryapranata H: Multicentre randomized trial comparing transport to primary angioplasty vs immediate thrombolysis vs combined strategy for patients with acute myocardial infarction presenting to a community hospital without a catheterization laboratory. The PRAGUE study. Eur Heart J 2000; 21(10): 823-31.

  13. Widimsky P, Budesinsky T, Vorac D, Groch L, Zelizko M, Aschermann M, Branny M, St’asek J, Formanek P; ‘PRAGUE’ Study Group Investigators. Long distance transport for primary angioplasty vs immediate thrombolysis in acute myocardial infarction. Final results of the randomized national multicentre trial-PRAGUE-2. Eur Heart J 2003; 24(1): 94-104.

  14. Nallamothu BK, Bates ER: Percutaneous coronary intervention vs fibrinolytic therapy in acute myocardial infarction: is timimg (almost) everything? Am J Cardiol 2003; 92: 824-6.

  15. De Luca G, Suryapranata H, Ottervanger JP, Antman EM: Time delay to treatment and mortality in primary angioplasty for acute myocardial infarction: every minute of delay counts. Circulation 2004; 109(10): 1223-5.

  16. Brodie BR, Hansen C, Stuckey TD, Richter S, Versteeg DS, Gupta N, Downey WE, Pulsipher M: Door-to-balloon time with primary percutaneous coronary intervention for acute myocardial infarction impacts late cardiac mortality in high-risk patients and patients presenting early after the onset of symptoms. J Am Coll Cardiol 2006; 47(2): 289-95.

  17. De Luca G, Suryapranata H, Stone GW, Antoniucci D, Tcheng JE, Neumann FJ, Van de Werf F, Antman EM, Topol EJ: Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. JAMA 2005; 293(14): 1759-65.

  18. Montalescot G, Barragan P, Wittenberg O, Ecollan P, Elhadad S, Villain P, et al: Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 2001; 344(25): 1895-903.

  19. Stone GW, Grines CL, Cox DA, et al: Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med 2002; 346(13): 957-66.

  20. Neumann FJ, Kastrati A, Schmitt C, et al: Effect of glycoprotein IIb/IIIa receptor blockade with abciximab on clinical and angiographic restenosis rate after the placement of coronary stents following acute myocardial infarction. J Am Coll Cardiol 2000; 35(4): 915-21.

  21. Antoniucci D, Rodríguez A, Hempel A, et al: A randomized trial comparing primary infarct artery stenting with or without abciximab in acute myocardial infarction. J Am Coll Cardiol 2003; 42(11): 1879-85. (ACE).

  22. Spaulding C, Henry P, Teiger E, Beatt K, Bramucci E, Carrie D, et al: Sirolimus-eluting versus uncoated stents in acute myocardial infarction. TYPHOON Investigators. N Engl J Med 2006; 355: 1093-1104.

  23. Laarman GJ, Suttorp MJ, Dirksen MT, van Heerebeek L, Kiemeneij F, Slagboom T, et al: Paclitaxel-eluting versus uncoated stents in primary percutaneous coronary intervention. N Engl J Med 2006; 355(11): 1105-13.

  24. Assessment of the Safety and Efficacy of a New Treatment Strategy with Percutaneous Coronary Intervention (ASSENT-4 PCI) investigators. Primary versus tenecteplase-facilitated percutaneous coronary intervention in patients with ST-segment elevation acute myocardial infarction (ASSENT-4 PCI): randomized trial. Lancet 2006; 367(9510): 569-78.

  25. ADVANCE MI Investigators. Facilitated percutaneous coronary intervention for acute ST-segment elevation myocardial infarction: results from the prematurely terminated ADdressing the Value of facilitated Angioplasty after Combination therapy or Eptifibatide monotherapy in acute Myocardial Infarction (ADVANCE MI) trial. Am Heart J 2005; 150(3): 391.

  26. Ellis SG, Armstrong P, Betriu A, Brodie B, Herrmann H, Montalescot G, et al: Facilitated percutaneous coronary intervention versus primary percutaneous coronary intervention: design and rationale of the Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events (FINESSE) trial. Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events Investigators. Am Heart J 2004; 147(4): E16.

  27. Armstrong PW; WEST Steering Committee. A comparison of pharmacologic therapy with/without timely coronary intervention vs. primary percutaneous intervention early after ST-elevation myocardial infarction: the WEST (Which Early ST-elevation myocardial infarction Therapy) study. Eur Heart J 2006; 27(13): 1530-8.

  28. Ortolani P, Marzocchi A, Marrozzini C, Palmerini T, Saia F, Serantoni C, Aquilina M, Silenzi S, Baldazzi F, Grosseto D, Taglieri N, Cooke RM, Bacchi-Reggiani ML, Branzi A: Clinical impact of direct referral to primary percutaneous coronary intervention following pre-hospital diagnosis of ST-elevation myocardial infarction. Eur Heart J 2006; 27(13): 1550-7.




2020     |     www.medigraphic.com